By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Oppenheimer has initiated coverage of Genomic Health, Thermo Fisher Scientific, and Fluidigm.

In a research note issued after the close of the market on Tuesday, analyst David Ferreiro placed a Perform rating on Genomic Health and a 12- to 18-month price target on its stock of $20. He estimated the firm's 2011 EPS at $.11 on revenues of $204.6 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.